Compare United Microelectronics Corp (UMC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Microelectronics Corp vs State Street SPDR S&P Biotech ETF — how do they compare? United Microelectronics Corp trades at $22.21 (market cap $56.28B), while State Street SPDR S&P Biotech ETF trades at $159.61. The key difference: United Microelectronics Corp pays a 1.77% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, United Microelectronics Corp nearer its low. Which is the better fit depends on your goals.
| UMC | XBI | |
|---|---|---|
Market Cap | $56.28B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $28.02 | $169.55 |
52-Week Low | $6.76 | $93.43 |
Enterprise Value | $53.32B | — |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UMC trades at $21.82, up 5.06% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a net income margin of 32.75% and ROE of 21.03%, though revenue has moderated from 2022 peaks. Recent news highlights sales growth, AI expansion plans, and mixed analyst sentiment amid volatility in the semiconductor sector.
Outlook is positive with earnings momentum and strategic investments in silicon photonics, but risks include competitive pressures and reliance on AI spending cycles. Analysts are divided, with 26.7% buy ratings versus 53.3% hold, suggesting cautious optimism for long-term growth despite near-term overbought signals.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
